STOCKHOLM, Sweden--(BUSINESS WIRE)--In the recently conducted interim analysis of the phase I/IIa study on the wound healing product ChronSeal® in which Tripep has a 10% ownership it was concluded that the group of patients randomized for placebo treatment but receiving standard of care at the time of the analysis was too small for allowing statistical analysis. The trends that could be drawn were so encouraging that the study will continue and thereby be expanded by 50% of the study population size at the time of the interim analysis. Also so far the study has shown that ChronSeal® is safe and that no serious or unexpected side effects have been reported. The final results are estimated to be obtained already during the first quarter of 2010.
